Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease – A cross-validation study

Ming Jang Chiu, Ta Fu Chen, Chaur Jong Hu, Sui Hing Yan, Yu Sun, Bing Hsien Liu, Yun Tsui Chang, Che Chuan Yang, Shieh Yueh Yang

研究成果: 雜誌貢獻文章同行評審

3 引文 斯高帕斯(Scopus)

摘要

Blood-based biomarker assays of plasma β-amyloid (Aβ) and tau have the advantages of cost-effective and less invasive for the diagnosis of Alzheimer's disease (AD). We used two independent cohorts to cross-validate the clinical use of the nanoparticle-based immunomagnetic assay of plasma biomarkers to assist in the differential diagnosis of early AD. There were in total 160 subjects in the derivation cohort, and 242 in the validation cohort both containing controls, mild cognitive impairment due to AD and AD dementia diagnosed according to the 2011 NIA-AA guidelines. The cutoff value for plasma Aβ1–42 (16.4 pg/ml) performed the best in differentiating between controls and patients with prodromal or clinical AD, with 92.5% for positive percent agreement (PPA), negative percent agreement (NPA), and overall rate of agreement (ORA). Aβ1–42 × tau (642.58) was useful for separating patients with dementia and prodromal states of AD, with 84.9% PPA, 78.8% NPA and 83% ORA.
原文英語
文章編號102182
期刊Nanomedicine: Nanotechnology, Biology, and Medicine
28
DOIs
出版狀態已發佈 - 八月 2020

ASJC Scopus subject areas

  • 生物工程
  • 醫藥(雜項)
  • 分子醫學
  • 生物醫學工程
  • 材料科學(全部)
  • 藥學科學

指紋

深入研究「Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease – A cross-validation study」主題。共同形成了獨特的指紋。

引用此